9830169C18Rik Activators
"9830169C18Rik Activators encompass a range of chemical compounds that, through their interaction with various cellular signaling pathways, serve to indirectly augment the activity of the protein 9830169C18Rik. Compounds like Forskolin and Zaprinast, by increasing intracellular cAMP levels, activate PKA, which may phosphorylate regulatory sites on 9830169C18Rik or associated proteins, thereby enhancing its activity. Similarly, Ionomycin and A23187, both of which increase intracellular calcium, could activate calcium-dependent signaling mechanisms that lead to the activation of 9830169C18Rik, assuming it is responsive to such signals. Sphingosine-1-phosphate, a lipid signaling molecule, interacts with its G-protein-coupled receptors to initiate downstream signaling cascades that could include the activation of 9830169C18Rik if it is a component of these pathways. Furthermore, the kinase inhibitor EGCG and the PKC activator PMA might indirectly enhance 9830169C18Rik activity by modulating the phosphorylation status of proteins in relevant signaling pathways that intersect with 9830169C18Rik's function.
Continuing with the modulation of kinase activity, LY294002 and U0126, inhibitors of PI3K and MEK respectively, may lift negative regulatory influences on 9830169C18Rik, assuming it is under the control of PI3K or MAPK/ERK signaling pathways. SB203580, by inhibiting p38 MAPK, could also remove inhibitory actions on 9830169C18Rik, if such inhibition exists. The phosphodiesterase inhibitors Rolipram and Zaprinast, by maintaining elevated cAMP levels, could similarly perpetuate a state of enhanced 9830169C18Rik activity. Anisomycin, although primarily a protein synthesis inhibitor, can activate stress-activated protein kinases that might lead to the activation of 9830169C18Rik through stress-response signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin acts as an ionophore for calcium, raising intracellular calcium levels and potentially activating calcium-dependent proteins. If 9830169C18Rik activity is modulated by calcium signaling, ionomycin could enhance its function. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is a kinase inhibitor with a broad range of targets. If 9830169C18Rik is regulated by a kinase that is inhibited by EGCG, this compound could result in the increased activity of 9830169C18Rik by reducing inhibitory phosphorylation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is an activator of protein kinase C (PKC). If 9830169C18Rik is downstream of PKC in a signaling pathway, PMA could enhance the functional activity of 9830169C18Rik by PKC-mediated signaling events. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P is a bioactive lipid that activates a family of G-protein-coupled receptors, which can lead to various downstream effects. If 9830169C18Rik is involved in a pathway downstream of S1P receptors, S1P could indirectly increase its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. If 9830169C18Rik is negatively regulated by a PI3K-dependent pathway, LY294002 could enhance its activity by alleviating this negative regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor, which would inhibit the MAPK/ERK pathway. If 9830169C18Rik is involved in a pathway negatively impacted by MAPK/ERK signaling, U0126 could potentially enhance its activity by reducing the MAPK/ERK-mediated suppression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK. If 9830169C18Rik functions are suppressed by p38 MAPK activity, inhibition of this kinase by SB203580 could lead to the enhanced activity of 9830169C18Rik. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore, which can increase intracellular calcium levels. If 9830169C18Rik is activated by calcium-dependent signaling, A23187 could be used to enhance its activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast inhibits phosphodiesterases, leading to an increase in cAMP levels. If 9830169C18Rik is regulated via cAMP-dependent pathways, Zaprinast could enhance its activity by increasing cAMP levels. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is another phosphodiesterase inhibitor that raises cAMP levels. Similar to Zaprinast, if 9830169C18Rik is modulated by cAMP, Rolipram could indirectly enhance its function. | ||||||